Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-20), b) 100 mL bottle (NDC 68180-722-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA

Presence of Foreign substance: identified as a dead ant.

Recall #: D-0306-2020
Affected scope: a) 4074 bottles b) 30,300 bottles
Initiated: November 1, 2019

Compiled from official public sources by the publisher. · Updated September 2026

Lupin Pharmaceuticals Inc. recalled Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-… - a low-severity action.

Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-… was recalled by Lupin Pharmaceuticals Inc. in November 13, 2019. Reason: Presence of Foreign substance: identified as a dead ant.. Check the official notice for the remedy. Verify recall #D-0306-2020 with the FDA Drug before acting.

The recall

Lupin Pharmaceuticals Inc. issued this low-severity FDA Drug recall-Presence of Foreign substance: identified as a dead ant..

Low
severity level: Class III
classification: November 13, 2019
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0306-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 1 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-20), b) 100 mL bottle (NDC 68180-722-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA

Reason for recall

Presence of Foreign substance: identified as a dead ant.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-0306-2020
Date reported	November 13, 2019
Date initiated	November 1, 2019
Recalling firm	Lupin Pharmaceuticals Inc.
Firm location	Baltimore, MD
Affected scope	a) 4074 bottles b) 30,300 bottles
Distribution	Product was distributed to major distributors/wholesalers throughout the United States.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0306-2020) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Presence of Foreign substance: identified as a dead ant.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on November 13, 2019. Severity: Low. Recall number: D-0306-2020.

Where was the recalled product distributed? ▼

Distribution: Product was distributed to major distributors/wholesalers throughout the United States..

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

Sankaijo BOTANICAL LAXATIVE (docusate sod… 2019-11-13 Selecto Wraps de Tomate, Tomato Wraps Ec… 2019-11-13 La Samaritana Tortillas (Harina de Trigo)… 2019-11-13 Casablanca brand Non-Pareils Sprinkles in… 2019-11-13

Similar Children & Baby Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Basic Reset Earth Wash Cleaner and Person… 2019-11-13 Miracle Facelift Masque, All Natural, The… 2019-11-13 Basic Reset Nuovi Skin Toner, Refined Ion… 2019-11-13 Nuovi Firming Masque, Renew and Reset, 2 … 2019-11-13

Compare this recall with CLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per … → · All Children & Baby Products recalls

This recall: FDA Drug, reported November 13, 2019. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026